
- Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11.
- ALNY has a 100% technical “Buy” opinion via Barchart.
- The company boasts a robust pipeline, recent FDA approvals, and dramatic projected revenue and earnings growth for 2025.
- Analyst sentiment is mostly bullish with high price targets.